Versamune®-based Therapies
Prostate Cancer
Key Facts
About PDS Biotechnology
PDS Biotech is focused on transforming how the immune system targets and fights disease through its Versamune® T-cell activating platform and its combination with the tumor-targeted IL-12 immunocytokine PDS01ADC. The company has demonstrated promising clinical results in HPV-positive cancers, including a median overall survival of 39.3 months in a Phase 2 head and neck cancer trial. With a growing pipeline in oncology and infectious disease vaccines, PDS Biotech aims to create a new generation of targeted immunotherapies.
View full company profileAbout PDS Biotechnology
PDS Biotech is focused on transforming how the immune system targets and fights disease through its Versamune® T-cell activating platform and its combination with the tumor-targeted IL-12 immunocytokine PDS01ADC. The company has demonstrated promising clinical results in HPV-positive cancers, including a median overall survival of 39.3 months in a Phase 2 head and neck cancer trial. With a growing pipeline in oncology and infectious disease vaccines, PDS Biotech aims to create a new generation of targeted immunotherapies.
View full company profileAbout PDS Biotechnology
PDS Biotech is focused on transforming how the immune system targets and fights disease through its Versamune® T-cell activating platform and its combination with the tumor-targeted IL-12 immunocytokine PDS01ADC. The company has demonstrated promising clinical results in HPV-positive cancers, including a median overall survival of 39.3 months in a Phase 2 head and neck cancer trial. With a growing pipeline in oncology and infectious disease vaccines, PDS Biotech aims to create a new generation of targeted immunotherapies.
View full company profileTherapeutic Areas
Other Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Erleada (apalutamide) | Johnson & Johnson | Approved |
| Nubeqa (darolutamide) | Bayer | Approved |
| Xtandi (enzalutamide) | Astellas Pharma | Approved |
| Proxalutamide (HS-10370) | Hansoh Pharma | Phase 3 |
| Darolutamide (Nubeqa) | Orion Corporation | Approved |
| Relacorilant + Enzalutamide | Corcept Therapeutics | Phase 2 |
| NBTXR3 | Nanobiotix | Phase 1/2 |
| Praluzatamab ravtansine (CX-2009) | CytomX Therapeutics | Phase 1/2 |
| Bavdegalutamide (ARV-110) | Arvinas | Phase 2 |
| ARV-766 | Arvinas | Phase 2 |
| Alpha DaRT | Alpha Tau Medical | Phase 1/2 |
| Prognostic Genomic Tests | Eurobio Scientific | Commercial |